The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects against Cryptococcus neoformans
Open Access
- 28 March 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 8, 535
Abstract
Cryptococcus neoformans is the most lethal pathogen of the central nervous system. The gold standard treatment of cryptococcosis, a combination of amphotericin B with 5-fluorocytosine, involves broad toxicity, high costs, limited efficacy and worldwide availability. Although the need for new antifungals is clear, drug research and development (R&D) is costly and time-consuming. Thus, drug repurposing is an alternative to R&D and to the currently available tools for treating fungal diseases. Here we screened a collection of compounds approved for use in humans seeking for those with anti-cryptococcal activity. We found that benzimidazoles class is a broad class of chemicals inhibiting C. neoformans growth. Mebendazole and fenbendazole were the most efficient antifungals showing in vitro fungicidal activity. Since previous studies showed that mebendazole reaches the brain in biologically active concentrations, this compound was selected for further studies. Mebendazole showed antifungal activity against phagocytized C. neoformans, affected cryptococcal biofilms profoundly and caused marked morphological alterations in C. neoformans, including reduction of capsular dimensions. Amphotericin B and mebendazole had additive anti-cryptococcal effects. Mebendazole was also active against the C. neoformans sibling species, C. gattii. To further characterize the effects of the drug a random C. gattii mutant library was screened and indicated that the antifungal activity of mebendazole requires previously unknown cryptococcal targets. Our results indicate that mebendazole is as a promising prototype for the future development of anti-cryptococcal drugs.Keywords
Funding Information
- Wellcome Trust (WT103212MF)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (573642/2008-7, 443586/2014-4, 300699/2013-1)
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/102.835/2012, 210.918/2015)
This publication has 60 references indexed in Scilit:
- The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Trends in Antifungal Drug Susceptibility of Cryptococcus neoformans Isolates Obtained through Population-Based Surveillance in South Africa in 2002-2003 and 2007-2008Antimicrobial Agents and Chemotherapy, 2011
- Cryptococcal Interactions with the Host Immune SystemEukaryotic Cell, 2010
- Deconstructing the Drug Development Process: The New Face of InnovationClinical Pharmacology & Therapeutics, 2010
- Estimation of the cost of large-scale school deworming programmes with benzimidazolesTransactions of the Royal Society of Tropical Medicine and Hygiene, 2010
- A Putative P-Type ATPase, Apt1, Is Involved in Stress Tolerance and Virulence in Cryptococcus neoformansEukaryotic Cell, 2010
- Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDSAIDS, 2009
- Binding of the Wheat Germ Lectin to Cryptococcus neoformans Suggests an Association of Chitinlike Structures with Yeast Budding and Capsular GlucuronoxylomannanEukaryotic Cell, 2008
- Cryptococcus neoformans Biofilm Formation Depends on Surface Support and Carbon Source and Reduces Fungal Cell Susceptibility to Heat, Cold, and UV LightApplied and Environmental Microbiology, 2007
- A Eukaryotic Capsular Polysaccharide Is Synthesized Intracellularly and Secreted via ExocytosisMolecular Biology of the Cell, 2006